65 related articles for article (PubMed ID: 2130679)
1. Effects of taurine and ursodeoxycholic acid on liver function tests in patients with cystic fibrosis.
Colombo C; Battezzati PM; Crosignani A; Assaisso M; Ronchi M; Giunta A
Acta Univ Carol Med (Praha); 1990; 36(1-4):148-51. PubMed ID: 2130679
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
[TBL] [Abstract][Full Text] [Related]
3. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
4. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
Lindblad A; Glaumann H; Strandvik B
Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
[TBL] [Abstract][Full Text] [Related]
5. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial.
Merli M; Bertasi S; Servi R; Diamanti S; Martino F; De Santis A; Goffredo F; Quattrucci S; Antonelli M; Angelico M
J Pediatr Gastroenterol Nutr; 1994 Aug; 19(2):198-203. PubMed ID: 7815243
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
Nakagawa M; Colombo C; Setchell KD
Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
[TBL] [Abstract][Full Text] [Related]
7. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
[TBL] [Abstract][Full Text] [Related]
8. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
[TBL] [Abstract][Full Text] [Related]
9. Effect of taurine supplements on growth, fat absorption and bile acid on cystic fibrosis.
Carrasco S; Codoceo R; Prieto G; Lama R; Polanco I
Acta Univ Carol Med (Praha); 1990; 36(1-4):152-6. PubMed ID: 2130680
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis.
Nilsell K; Angelin B; Leijd B; Einarsson K
Gastroenterology; 1983 Dec; 85(6):1248-56. PubMed ID: 6628924
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and bile acid composition in the Rhesus Monkey.
Sarva RP; Fromm H; Farivar S; Sembrat RF; Mendelow H; Shinozuka H; Wolfson SK
Gastroenterology; 1980 Oct; 79(4):629-36. PubMed ID: 7409382
[TBL] [Abstract][Full Text] [Related]
12. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis.
Batta AK; Salen G; Mirchandani R; Tint GS; Shefer S; Batta M; Abroon J; O'Brien CB; Senior JR
Am J Gastroenterol; 1993 May; 88(5):691-700. PubMed ID: 8480734
[TBL] [Abstract][Full Text] [Related]
14. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis.
Podda M; Ghezzi C; Battezzati PM; Crosignani A; Zuin M; Roda A
Gastroenterology; 1990 Apr; 98(4):1044-50. PubMed ID: 1968871
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.
Colombo C; Crosignani A; Assaisso M; Battezzati PM; Podda M; Giunta A; Zimmer-Nechemias L; Setchell KD
Hepatology; 1992 Oct; 16(4):924-30. PubMed ID: 1398498
[TBL] [Abstract][Full Text] [Related]
16. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C.
Takano S; Ito Y; Yokosuka O; Ohto M; Uchiumi K; Hirota K; Omata M
Hepatology; 1994 Sep; 20(3):558-64. PubMed ID: 7521313
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.
Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S
Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver.
Benedetti A; Alvaro D; Bassotti C; Gigliozzi A; Ferretti G; La Rosa T; Di Sario A; Baiocchi L; Jezequel AM
Hepatology; 1997 Jul; 26(1):9-21. PubMed ID: 9214446
[TBL] [Abstract][Full Text] [Related]
19. [New aspects of cystic fibrosis liver disease].
Lerner A; Rivlin J
Harefuah; 1992 May; 122(9):593-4. PubMed ID: 1526587
[No Abstract] [Full Text] [Related]
20. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
